While the precise mechanism of action of ofatumumab is unknown, it is understood that the FAB portion of ofatumumab selectively binds to and inhibits CD20, a transmembrane phosphoprotein expressed on B lymphocytes [9,10,12]; ofatumumab binds to a region of the CD20 different from that of other ...
5.13.2Mechanism of action Ofatumumabis a fully humanized IgG1κ immunoglobulinmonoclonal antibodythat binds specifically to both the small and large extracellular loops of the CD20 molecule on B-cell. TheCD20 antigenis expressed on normal B lymphocytes (pre–B- to mature B-lymphocyte) and on B-...
Its mechanism of action includes complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Combining OFA with cytotoxic chemotherapy may lead to elimination of additional tumor cells by alternate mechanisms such as apoptosis via alkylating agents....
Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAbs) used in the treatment of chronic lymphocytic l... NA Baig,RP Taylor,MA Lindorfer,... - 《Leukemia & Lymphoma》 被引量: 46发表: 2012年 Ofatumumab: a novel anti-CD20 monoclonal antibody...
Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAbs) used in the treatment of chronic lymphocytic l... NA Baig,RP Taylor,MA Lindorfer,... - 《Leukemia & Lymphoma》 被引量: 46发表: 2012年 Ofatumumab: a novel anti-CD20 monoclonal antibody...
Ofatumumab is a human monoclonal antibody that targets the CD20 protein, which is expressed on the surface of both normal and malignant B-cells. This mechanism of action allows for a greater response from the immune system against these cancerous cells. “We are exceedingly proud to receive the...
Ofatumumab has demonstrated a higher potency and a longer duration of efficacy than rituximab in several preclinical model studies and even kills rituximab refractory B cells, indicating a different mechanism of action that could offer an advantage in the clinic. Results from this first in human ...
Complement-dependent cytotoxicity (CDC) involves translocation of the CD20 molecule into lipid rafts, which are involved in cell signalling and receptor trafficking.The mechanism by which ofatumumab exerts a therapeutic effect in multiple sclerosis patients is unknown but is presumed to still occur as ...
Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAbs) used in the treatment of chronic lymphocytic l... NA Baig,RP Taylor,MA Lindorfer,... - 《Leukemia & Lymphoma》 被引量: 46发表: 2012年 Ofatumumab: a novel anti-CD20 monoclonal antibody...
The mechanism of action of OFA in FSGS recurrence requires further elucidation. Whether B-cell depletion is responsible for disease remission is complicated by dem- onstration of direct binding of RTX to podocytes [17], although the validity of this has been questioned and an effect on ...